


Cell Chemical Biology

Serotonin is a common thread linking different classes of antidepressants

Graphical abstract



Authors

Colby E. Witt, Sergio Mena, Jordan Holmes, ..., Patrick Schloss, Thorsten Lau, Parastoo Hashemi

Correspondence

phashemi@imperial.ac.uk

In brief

Using *in vivo* voltammetry (fast-scan cyclic voltammetry (FSCV) and fast-scan controlled adsorption (FSCAV)) in mice, Witt, Mena et al. found that acute administration of antidepressants of different classes similarly raises serotonin levels.

Highlights

- Antidepressants with different modes of action increase basal extracellular serotonin
- Both Uptake 1 and Uptake 2 inhibition raise serotonin levels
- Escitalopram induces rapid SERT internalization
- Ketamine increases serotonin by inhibition of histamine



Article

Serotonin is a common thread linking different classes of antidepressants

Colby E. Witt,^{1,9} Sergio Mena,^{2,9} Jordan Holmes,¹ Melinda Hersey,^{1,3} Anna Marie Buchanan,^{1,3} Brenna Parke,² Rachel Saylor,¹ Lauren E. Honan,¹ Shane N. Berger,¹ Sara Lumbreras,⁷ Frederik H. Nijhout,⁴ Michael C. Reed,⁵ Janet Best,⁶ James Fadel,³ Patrick Schloss,⁷ Thorsten Lau,^{7,8} and Parastoo Hashemi^{1,2,10,*}

¹Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC, USA

²Department of Bioengineering, Imperial College London, London, UK

³Department of Pharmacology, Physiology and Neuroscience, University of South Carolina School of Medicine, Columbia, SC, USA

⁴Department of Biology, Duke University, Durham, NC, USA

⁵Department of Mathematics, Duke University, Durham, NC, USA

⁶Department of Mathematics, The Ohio State University, Columbus, OH, USA

⁷Department of Psychiatry and Psychotherapy, Biochemical Laboratory, Central Institute of Mental Health, Medical Faculty, Mannheim, Heidelberg University, Mannheim, Germany

⁸Department of Neuroanatomy, Mannheim Centre for Translational Neuroscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

⁹These authors contributed equally

¹⁰Lead contact

*Correspondence: phashemi@imperial.ac.uk

<https://doi.org/10.1016/j.chembiol.2023.10.009>

SUMMARY

Depression pathology remains elusive. The monoamine hypothesis has placed much focus on serotonin, but due to the variable clinical efficacy of monoamine reuptake inhibitors, the community is looking for alternative therapies such as ketamine (neurogenesis theory of antidepressant action). There is evidence that different classes of antidepressants may affect serotonin levels; a notion we test here. We measure hippocampal serotonin in mice with voltammetry and study the effects of acute challenges of escitalopram, fluoxetine, reboxetine, and ketamine. We find that pseudo-equivalent doses of these drugs similarly raise ambient serotonin levels, despite their differing pharmacodynamics because of differences in Uptake 1 and 2, rapid SERT trafficking, and modulation of serotonin by histamine. These antidepressants have different pharmacodynamics but have strikingly similar effects on extracellular serotonin. Our findings suggest that serotonin is a common thread that links clinically effective antidepressants, synergizing different theories of depression (synaptic plasticity, neurogenesis, and the monoamine hypothesis).

INTRODUCTION

Depression is one of society's most critical health issues. Antidepressants are some of the most prescribed medicines globally; they differ significantly in their structure and functions, carry with them side effects and a clinical regime where antidepressant type and dosage are altered on a trial-and-error basis.¹ Importantly, there is quite some speculation about whether clinical responses to antidepressants are significantly meaningful with respect to placebo, exercise, or psychotherapy.^{2,3} The community has not settled on a unifying pathophysiological basis of depression, as such it is nearly impossible to systematically develop novel, more effective antidepressants. To improve a drug's efficacy, it is critical to identify a measurable biomarker of disease and to investigate the response of the biomarker to potential therapeutics. For depression, much traditional focus was on serotonin, spurred by the monoamine hypothesis of depression.¹ Over the last 3 decades, the serotonin hypothesis

has moved in and out of the spotlight, recently enjoying a resurgence because of clinical trials targeting depression with psychedelics (with affinity for serotonin receptors).⁴ In recent years the community has looked for alternative theories of depression and treatment strategies, including other monoamines (e.g., norepinephrine) and the promotion of synaptic plasticity and neurogenesis via ketamine's effects on NMDA receptors.⁵ Despite the surface-level differences in the mode of action of different classes of antidepressants (including norepinephrine reuptake inhibitors (NRIs) and ketamine), there is emerging evidence that these agents may indirectly target serotonin.^{6–9}

In recent work, we have shown that ambient serotonin concentrations correlate with depression phenotypes in mice (i.e., the lower the serotonin the more intense the phenotype of depression).¹⁰ This work lead us to concur with the monoamine hypothesis that serotonin is likely a valid biomarker of depression. In this work, we extended this notion to antidepressants by using *in vivo* voltammetry to measure hippocampal serotonin in mice (fast



scan cyclic voltammetry (FSCV) and fast scan controlled-adsorption voltammetry (FSCAV)) and studied the effects on serotonin of acute challenge with two different SSRIs (fluoxetine and escitalopram), an NRI (reboxetine), and ketamine. We chose to study the hippocampus because of the many prior studies describing the importance of this region in the pathology of depression^{11,12} and the finding of structural differences in the hippocampus between control and depressed patients^{13–15} and after SSRI use.¹⁶ We found that pseudo-equivalent doses of these drugs raised ambient serotonin levels with similar magnitude and kinetics, despite their very different pharmacodynamics. We then took in-depth experimental and analysis approaches to understand how these drugs modulate the serotonin system. We observed innate, low frequency (several minutes) oscillations in the concentration of ambient serotonin that changed after SSRIs and the NRI but not after ketamine. We hypothesized that changes were due to differences in Uptake 1 and Uptake 2 mediation of serotonin reuptake. We verified this hypothesis via Michaelis-Menten (M-M) analysis of experimental data from evoked release of serotonin with FSCV and showed that inhibition of SERTs (Uptake 1) is intrinsic to SSRIs and that inhibition of Uptake 2 transporters follows the NRI. Furthermore, we found critical differences between fluoxetine and escitalopram. The response to escitalopram was dynamic and did not reach steady state, an effect we hypothesized to be due to rapid shuttling of SERTs in and out of cell membranes. Proof of principle for this notion was provided in a cellular model of serotonin transmission in serotonergic neurons. Finally, we suggested that the effect of ketamine on serotonin may be via inverse histaminergic modulation of serotonin and showed via further experiments that ketamine is a potent inhibitor of evoked histamine.

Although these drugs, which are all considered antidepressants, have very different pharmacodynamics, they have in common direct or indirect effects on serotonin. This finding signifies serotonin may synergize the different theories of depression and that the community should consider the heterogeneous nature of how depression affects serotonin and its analogs when looking at future design of drugs.

RESULTS

Full values and statistics can be found in the extended data section in the SI

How do antidepressants with different modes of action affect ambient extracellular serotonin?

Figure 1A shows the experimental paradigm for serotonin voltammetry. Animals were anesthetized, underwent stereotaxic surgery whereby a stimulating electrode was placed in the medial forebrain bundle (MFB), and a carbon fiber microelectrode (CFM) was placed in the CA2 region of the hippocampus. FSCV was used to identify an area where electrically evoked serotonin was present. The experimental mode was then switched to FSCAV to acquire minute-to-minute basal level measurements. After 30 min of control files, 5 mL kg⁻¹ saline was given intraperitoneally (*i.p.*), and 30 min after that a drug was given (*i.p.*). 60 min after drug files were collected, FSCV was reinstated to assess the effect of the drug.

Figure 1B shows representative FSCV and FSCAV color plots, cyclic voltammograms (CV), and current vs. time (IT) (for FSCV).

The black space in the FSCAV color plot indicates the holding period. Figure 1C shows the ambient serotonin levels after drug challenge with escitalopram, fluoxetine, reboxetine and ketamine. Each trace is an average of 5 animals $\pm$ SEM (error bars). Figure 1D shows the structure and mode of action for each agent.

A repeated measures analysis of variance (ANOVA) and analysis of covariance (ANCOVA) with *post-hoc* comparisons were used to analyze time points and slopes. Saline administration did not have a significant effect with respect to control prior to escitalopram, fluoxetine, reboxetine, and ketamine (all statistical comparisons are extensively described in the [supplemental information](#)). Sixty minutes after drug, escitalopram, fluoxetine, reboxetine, and ketamine significantly increase serotonin. The fastest rate of increase was found after escitalopram, which was significantly higher than fluoxetine and ketamine but not reboxetine.

Serotonin reuptake kinetics between different antidepressants

We performed power spectra density analysis (PSD) in FSCAV experiments with these 4 antidepressants. Figure 2A(i) shows a representative example of the filtered FSCAV data collected for 60 min before (black) and 60 min after fluoxetine (blue). Figure 2A(ii) is the mean and SEM ($n = 5$ mice) normalized PSD before drug (black) and after drug (blue). Figure 2A(iii) is a violin plot showing the distribution of the sum of power-weighted frequencies from the power spectra. Figures 2B, 2C, and 2D show the same data and analysis for escitalopram (green), reboxetine (red), and ketamine (purple). Using the sum of power-weighted frequencies (a measure of displacement of the whole power spectra, see [STAR Methods](#) section), we found the weighted frequencies increased after administration of fluoxetine and escitalopram (suggesting Uptake 1 inhibition), decreased after administration of reboxetine (implying Uptake 2 inhibition) and did not change after ketamine administration.

To further test how these agents changed the profile of serotonin reuptake, we performed FSCV analysis of evoked serotonin. In Figure 2(iv) we show control (black) and 60 min after drug (color) stimulated hippocampal serotonin release. We found that the maximum amplitude of release and clearance rate significantly increased 60 min after administration of fluoxetine, escitalopram, and reboxetine but not ketamine.

Next, we fit these responses with the M-M model of dual reuptake (Uptake 1 and 2) shown in Equation 1:

$$dC(t)/dt = R(t)(1 - A(t)) - \alpha \frac{V_{max1} \cdot C(t)}{K_{m1} + C(t)} - \beta \frac{V_{max2} \cdot C(t)}{K_{m2} + C(t)} \quad (\text{Equation 1})$$

Where $C(t)$, $R(t)$, and $A(t)$ represent the concentration of the neurotransmitter, evoked release rate, and autoreceptor control at time t , respectively. V_{max} and K_m are M-M parameters and α and β are the weights of Uptake 1 and Uptake 2. This equation was previously developed to fit to evoked FSCV serotonin traces, and it extracts information on the rate of release and reuptake of neurotransmitters taken up by Uptake 1 and 2 transporters.¹⁷ In this model, Uptake 1 represents a high-affinity, low-capacity system (serotonin transporters (SERTs)), and Uptake 2 is a low-affinity, high-capacity system (norepinephrine, dopamine, organic cation, and plasma membrane monoamine transporters (NETs, DATs,




Figure 1. Ambient serotonin response to different antidepressants

(A) Illustration of experimental paradigm for *in vivo* voltammetry for serotonin measurements with FSCV and FSCAV. First, mice were anesthetized and placed in a stereotaxic device, a CFM was placed in the CA2 region of the hippocampus, and control FSCV was performed upon stimulation of the MFB. Subsequently, FSCAV files were taken over 30 min, at which point a saline *i.p.* injection was given. FSCAV files were then taken for another 30 min, and then an *i.p.* injection of antidepressant was given. FSCAV files were taken for another 60 min after the drug injection. Finally, an FSCV file 60 min post-drug was acquired.

(B) Representative *in vivo* serotonin color plots from FSCV (left) and FSCAV (right) signals. The FSCV plot has an inset cyclic voltammogram (top) and current vs. time trace (bottom). The FSCAV plot has an inset cyclic voltammogram where the serotonin peak was integrated for its charge (Q).

(C) Effect of antidepressant therapies on ambient serotonin levels. After 30 min of baseline measurements, 5 mL kg⁻¹ of saline was administered (*i.p.*). Then, 20 mg kg⁻¹ fluoxetine (blue), 10 mg kg⁻¹ escitalopram (green), 20 mg kg⁻¹ reboxetine (red), or 10 mg kg⁻¹ ketamine (purple) were administered *i.p.* 30 min after saline. Each trace shows the average ($n = 5$ mice from a mixed sex cohort) with standard error of the mean (SEM) as error bars.

(D) Table outlining the antidepressants used in this study, their structure, classification as an antidepressant and proposed mechanisms of action.

the blue trace in Figure 2F) and a weak change to K_{m1} , since even though with a much lower affinity, reboxetine can also bind to SERTs. Ketamine does not change the kinetics of the curve. Escitalopram is the most unusual response in that it cannot be fit with a change in K_{m1} (consistent with SERT inhibition). Here, we also needed to substantially alter V_{max1} to fit the curve (red curve in Figure 2F). Competitive uptake inhibition should not ordinarily change V_{max} , therefore, we found it interesting to study escitalopram more thoroughly via detailed dose response experiments.

A temporo-dose response for escitalopram

To evaluate the effects of different doses of escitalopram on serotonin, we administered 4 different doses to cohorts of mice and performed a time after drug analysis for each dose (1–30 mg kg⁻¹ in Figures 3A–3D(i)). The data are from female mice, however, male mice respond similarly and are shown in the supplemental information (Figure S1). The control (before drug) response is shown in black for all doses and then shown 5, 30, 60, 90, and 120 min after escitalopram. We found no significant differences in serotonin maximum amplitude and elimination half-life between mice of different ages (see Figure S3 in the SI). Figure 3E depicts our pharmacokinetic model, the four-compartment model (FCM),

OCTs, and PMATs)). The results of the modeling (shown as ratio of change with respect to control) are in the table in Figure 2E. Figure 2F is a synthesized response where hypothetical scenarios are modeled. These scenarios are Uptake 2 inhibition via K_{m2} (blue), Uptake 1 inhibition via K_{m1} (orange), and Uptake 1 inhibition (via change in both K_{m1} and V_{max1} ; red). SERT inhibition with fluoxetine follows a typical orthosteric inhibition profile, where a change in K_{m1} (orange curve in Figure 2F) can easily fit the curve. Uptake inhibition with reboxetine follows mainly Uptake 2 inhibition, where the curve can be modeled by primarily a change in K_{m2} (resembling




Figure 2. Serotonergic oscillations from ambient measurements and FSCV responses

(A) Data representing fluoxetine, (B) Data representing escitalopram, (C) Data representing reboxetine, (D) Data representing ketamine, (i) Representative FSCAV serotonin (ser.) extracellular oscillations over 60 min with control in black and post-drug administration in color. Time series were bandpass filtered (3rd order Butterworth filter with cutoff frequencies of 0.0008 Hz and 0.005 Hz) to remove high frequency noise and slow drug effects on the serotonin extracellular levels. (ii) Normalized mean and SEM ($n = 5$ animals) power spectrum density of control FSCAV data (black) and post-drug data (color). (iii) Violin plots of the distribution of power-weighted frequencies (WF) ($n = 5$ animals for each drug) of the power spectra pre- (gray) and post-drug (color) administration shown in ii. (iv) current vs. time profiles from stimulated serotonin release in the CA2 pre- and post-drug administration ($n = 5$ mice for fluoxetine, reboxetine and ketamine and $n = 9$ for escitalopram), error bars are SEM. The solid black traces are from control files and the colored traces are 60 min post-drug administration (*i.p.*). Modeled data are laid over their respective traces with dots. The start and end of stimulation is shown with a red bar.

(E) Table of M-M terms from modeled data in iv. Each value is the ratio of change post-drug with respect to the control state.

(F) Modeled traces with varied M-M terms. Control modeled trace is shown in black ($K_{m1} = 2$ nM, $V_{\max 1} = 12$ nM s⁻¹, $K_{m2} = 170$ nM, $V_{\max 2} = 780$ nM s⁻¹), competitive Uptake 2 inhibition (K_{m2} is 10-fold the control value) in blue, competitive Uptake 1 inhibition (K_{m1} is 10-fold the control value) in orange, and Uptake 1 (K_{m1} is 10-fold and $V_{\max 1}$ is 50% of the control values) in red.

used to obtain an estimation of escitalopram concentration in a mouse brain. This model was developed based on prior experimental studies of pharmacokinetics of escitalopram with mice and rats (see methods). In this model, we simulate the physiological path of an acute *i.p.* injection of escitalopram, from 4 different compartments in the body with different concentrations of the drug: the peritoneum ($C_0(t)$), plasma ($C_1(t)$), brain extracel-

lular space ($C_2(t)$), and periphery ($C_3(t)$). The arrows of the model depict interchange of escitalopram between compartments. The rate constants, k , determine the speed of escitalopram interchange (nM min⁻¹) from one compartment to another or to secretion (k_{10}). The model considers the partial bioavailability of the drug after peritoneal injection, the percentage of protein binding (e.g., albumin) to the drug in plasma, and the retention




Figure 3. Acute dose response for escitalopram

(A) 1 mg kg⁻¹ (B) 3 mg kg⁻¹ (C) 10 mg kg⁻¹ (D) 30 mg kg⁻¹. (i) Evoked serotonin concentration vs. time traces from the CA2 region of the hippocampus of female mice before and after escitalopram (escit) administration ($n = 4$ animals each dose, mean $\pm$ SEM). (ii) Modeled serotonin concentration vs. time traces from the control data and after changing K_{m1} based on a simulated concentration of escitalopram in the hippocampus with time according to the pharmacokinetic model depicted in (E) (see STAR Methods section for a detailed description of the model). Compartment rate constants are obtained from literature of previous pharmacokinetic models of escitalopram in mice.¹⁹

(F–H) Modeled changes in maximum release rate of serotonin (F), K_{m1} (G), and V_{max1} (H) for each dose and over time after drug injection.

(I) FSCAV recordings of absolute concentrations of extracellular serotonin following the same experimental paradigm as described in Figure 1 for 3 different doses of escitalopram (mixed sex cohorts, $n = 5$ animals for 1 mg kg⁻¹ dose, $n = 7$ animals for 3 mg kg⁻¹ and 10 mg kg⁻¹ doses).

of escitalopram in the brain due to binding to SERTs. Solving the system of equations provides IT traces for escitalopram for each compartment.

Figures 3A–3D(ii) are the results of the theoretical temporodose response where K_{m1} is altered as per theoretical uptake inhibition¹⁸ of SERTs from escitalopram, while the rest of the release and uptake parameters are kept constant with respect to control. In these theoretical curves, as the dose increases, both maximum amplitude and $t_{1/2}$ of reuptake increase. In terms of the temporal response, for the 1 mg kg⁻¹ dose, 5 min after drug administration, the response is not meaningfully different from control, and the 30-, 60-, 90-, and 120-min responses are not substantially different from each other (the curves are on top of each other), since the modeled concentration of escitalo-

pram (Figure 3E) does not substantially change. For the 3 mg kg⁻¹ dose, this behavior is repeated. For the 10 and 30 mg kg⁻¹ doses, the 5-min responses are not different from the later time points due to higher doses increasing escitalopram in the brain more rapidly. Figures 3F–3H show the ratio changes of maximum release, K_{m1} and V_{max1} . In Figure 3F, the ratio of release amplitude does not substantially change with time for the 1 mg kg⁻¹ dose. For all other doses, it falls with time. For all doses, the K_{m1} increases with time. A finding of interest is that while at 1 mg kg⁻¹ after 5 min the K_{m1} increases, at 3 mg kg⁻¹ after 5 min K_{m1} does not increase (inset). This is contradictory since escitalopram's effects on K_{m1} should be stronger as the dose increases. In general, V_{max1} decreases with time for all doses. Another finding of interest here is that for 3 and




Figure 4. Voltammetric and fluorescent analysis of the effect of SSRIs on serotonergic neurons

(A) Immunofluorescence of cell surface-located SERT molecules. Fluorescence signals for SERT antibodies targeted against the second extracellular loop localized to neurites and cell bodies of 1C11^{5-HT}.

(B) Representative regions of interest used for quantification of SERT cell surface density in absence and presence of 1 μM escitalopram with and without high KCl-induced serotonin release 2 min after administration.

(C) Average and SEM (n = 80) calculated SERT density in cell cultures 2 and 5 min after 15 mM KCl and/or 1 μM escitalopram administration. High KCl evoked serotonin release results in elevated SERT cell surface densities and diminishes acute escitalopram-induced SERT internalization.

(D) The fluorescent SERT substrate ASP* is taken up by 1C11^{5-HT} cells and localizes to neurites and cell bodies.

(legend continued on next page)

10 mg kg⁻¹, $V_{\max 1}$ increases 5 min after drug administration. This is contradictory since escitalopram should decrease the apparent $V_{\max 1}$. Figure 3I is a comparison of the effects on the basal serotonin levels in separate cohorts of mice for 1, 3, and 10 mg kg⁻¹. We chose to compare these three doses to gather more information on the similarity between K_{m1} of the 3 and 10 mg kg⁻¹ doses. After a control period of 30 min, a 5 mL kg⁻¹ saline *i.p.* injection was given, and files were collected for another 30 min. After this, the drug was given, and the serotonin levels were measured for a further 60 min. Saline did not have a significant impact on the measured extracellular levels of serotonin prior to a dose of 1 mg kg⁻¹, 3 mg kg⁻¹, and 10 mg kg⁻¹. At the end of this period, serotonin increased when animals were given 1 mg kg⁻¹, 3 mg kg⁻¹, and 10 mg kg⁻¹ doses. The fastest rate of increase of extracellular serotonin was found to be after administration of a dose of 10 mg kg⁻¹, which was significantly higher than after a dose of 3 mg kg⁻¹ and 1 mg kg⁻¹. An interesting finding is that 1 mg kg⁻¹ causes a higher rate of serotonin increase vs. 3 mg kg⁻¹.

SERT expression/function in cellular model of in vivo-like serotonergic transmission

We studied SERT expression and function in a cellular model of serotonergic transmission. Figure 4A shows immunofluorescence of cell surface-located SERTs.^{20,21} Figure 4B are representative regions of interest where SERTs were quantified at rest, 2 min after potassium chloride (KCl) stimulation, 1 μ M escitalopram, and with both KCl and escitalopram. Figure 4C shows that escitalopram caused significant reductions in SERT expression after 2 and 5 min with respect to control, as seen previously for longer SSRI exposure (>2 h).²² KCl stimulation and a combination of KCl and escitalopram caused an increase in SERT expression after 2 and 5 min (significant at 5 min). These data show that KCl stimulation and a combination of KCl stimulation and escitalopram increase surface SERT density.

Figure 4D shows that the fluorescent SERT substrate ASP⁺ is taken up by the cells and localized to neurites and cell bodies. Figure 4E shows example regions of interest used for quantification of SERT uptake at rest, with electrical stimulation, 2 min after 1 μ M escitalopram, and with electrical stimulation and escitalopram. Figure 4F shows that ASP⁺ uptake diminished 2 min and 5 min after escitalopram (significant). Electrical stimulation alone and a combination of electrical stimulation and escitalopram increased ASP⁺ uptake after 2 and 5 min (near significant). These data show that, in synergy with increasing SERT density, electrical stimulation and escitalopram increase SERT activity.

Next, we chose to add serotonin (0.1 μ M and 1 μ M) to mimic both, chemically or electrically induced exocytotic serotonin

release. In doing so, we wanted to test whether serotonin on its own was capable of producing effects similar to induced neurotransmitter release. Indeed, acute application of only serotonin (0.1 μ M and 1 μ M) resulted in increased ASP⁺ uptake after 2 min and 5 min (Figure 4G). Adding escitalopram to the excess serotonin model was not able to reverse the increase in ASP⁺ uptake. This increased reuptake behavior did not extend to another SSRI, fluoxetine. Figure 4H is a comparison of ASP⁺ uptake in the presence of 1 μ M escitalopram or 10 μ M fluoxetine with the cells at rest or 5 min after electrical stimulation. Without stimulation, fluoxetine did not significantly affect ASP⁺ uptake, while escitalopram significantly decreased ASP⁺ uptake. Fluoxetine + electrical stimulation did not significantly affect ASP⁺ uptake. These data show that this phenomenon of increased ASP⁺ reuptake is limited to escitalopram and not fluoxetine.

Figure 4I are voltammetric recordings in the cells 5 and 75 min after the administration of escitalopram at 3 different doses (0.1 μ M, 0.5 μ M, and 1 μ M). The average traces were fitted with the two-reuptake M-M equation shown previously. Figures 4J–4L show the fitted ratio values with respect to the control state of $R(t)_{\max}$, K_{m1} and $V_{\max 1}$, 5 and 75 min after the administration of escitalopram for each dose. Interestingly, shortly after escitalopram (5 min), we see an increase in the rate of serotonin reuptake for 0.1 μ M and 1 μ M and no substantial effect for the 0.5 μ M dose. The reuptake rate slows progressively for all doses up to 75 min after this. These data provide chemical evidence that, as a result of escitalopram administration, serotonin can be reuptaken at a faster rate (depending on dose and time) due to increased SERT expression.

Histamine mediates Ketamine's effects on ambient serotonin

In this experimental paradigm, we administered ketamine (10 mg kg⁻¹ *i.p.*) and monitored the changes in evoked histamine and serotonin dynamics over 100 min in the posterior hypothalamus (PH) of mice. Figure 5A shows representative examples of control histamine and serotonin color plots in the PH (top) and 40 min after administration of ketamine (bottom). Interpretation of these histamine/serotonin color plots can be found elsewhere in great detail.²³ Briefly, evoked histamine release inhibits serotonin firing (via H3 receptors), the histamine and serotonin events are denoted in the color plot (Figure 5A) and the concentration vs. time profiles ($n = 5$ animals, mean $\pm$ SEM) are shown in Figure 5B. Ketamine induced a rapid decrease in the maximum amplitude of histamine release, with no significant effect on clearance rate 10 min after injection. Overall, we found significantly less inhibition of serotonin 10 min after drug injection. Figure 5C shows the average and SEM of the maximum amplitude

(E) Representative regions of interest used for quantification of SERT uptake in absence and presence of 1 μ M escitalopram with (evoked) and without (resting) electrical stimulation for serotonin release.

(F) Average and SEM ($n = 37$) ASP⁺ uptake measurements in cell cultures after evoked release of serotonin and/or 1 μ M escitalopram administration. Electrically evoked serotonin release results in increased uptake of fluorescent SERT substrate 2 and 5 min after stimulation while escitalopram treatment on its own diminishes SERT-dependent uptake. (Note: more uptake reflects more functional SERT molecules; less uptake means either internalized or inhibited SERT molecules).

(G) Average and SEM ($n = 37$) ASP⁺ uptake under administration of serotonin (0.1 μ M or 1 μ M), escitalopram (1 μ M) or both.

(H) Average and SEM ($n = 50$) comparison of ASP⁺ uptake by 1C11^{5-HT} exposed to either 1 μ M escitalopram or 10 μ M fluoxetine (fluox.) during rest or 5 min after electrical stimulation. Compared to escitalopram treatment, fluoxetine treatment did not significantly affect ASP⁺ uptake.

(I) Average and SEM ($n = 3$ cell dishes) evoked voltammetric recordings of serotonin release in control state and 5 and 75 min after escitalopram administration (0.1 μ M, 0.5 μ M, 1 μ M). (J–L) Fitted M-M parameters ($R(t)_{\max}$, K_{m1} , and $V_{\max 1}$) of the concentration vs. time traces shown in panel I. Dashed lines represent a ratio of 1 in G and J–L and the control levels in H.




Figure 5. Combined effects of ketamine on the histaminergic and serotonergic systems *in vivo*

(A) Representative color plots for simultaneous histamine and serotonin monitoring pre-ketamine administration (top) and 40 min post-ketamine administration (bottom) with the associated CV overlaid.

(B) IT curves for histamine (top) and serotonin (bottom) pre- and post-ketamine (mean $\pm$ SEM, $n = 5$ animals).

(C) Evoked histamine amplitude (top) and serotonin inhibition (bottom) over time (mean $\pm$ SEM, $n = 5$ animals). The darker data bars represent the amplitudes of the traces shown in B. Dashed line represents the mean value pre-drug administration.

(D) Suggested mechanism of action of ketamine on histamine and serotonin.

of histamine (top) and serotonin inhibition (bottom) over time. The effects of ketamine are sustained 100 min after injection.

DISCUSSION

Antidepressants with differing modes of action increase basal extracellular serotonin

Little progress has been made toward improving the clinical efficacy of antidepressants since the 1950s where the first of these agents (monoamine oxidase inhibitors (MAOIs)) were discovered, up to the modern day where “atypical” treatments such as ketamine are currently being explored. Importantly, there is now heated discussion about whether clinical responses to antidepressants (historical or modern) are even considered significantly meaningful with respect to placebo, exercise, or psychotherapy.^{2,3,24}

The overarching issue is that there are no reliable pre-clinical screening tools for antidepressants. Traditionally, potential antidepressant efficacy was screened using the forced swim test (FST) in rodents.²⁵ The length of time it took for animals to enter a learned helplessness state was improved by acute injections of potential antidepressants.²⁶ While many agents created this behavioral shift in rodents, they failed at clinical trials.²⁷ Moreover, few animal models have adequately captured behavioral changes in response to a chronic antidepressant regime (that humans undergo).^{28–32} As such, pharmaceutical companies dramatically toned down their antidepressant drug discovery efforts over the last 15 years and the larger research community, more recently, is raising serious concerns about the validity of the FST to accurately reflect depression phenotypes.^{33–36}

It is nearly impossible to systematically develop more effective antidepressants without a working hypothesis of the chemical

basis of depression. A screening process would ideally measure a biomarker of disease and gauge the response of this biomarker to potential therapeutics. Because of the monoamine hypothesis of depression, serotonin has long been speculated as a biomarker; however, because serotonin is difficult to measure *in vivo* and SSRIs have variable clinical efficacy, serotonin has become unpopular as a depression target in recent years and the research community have focused on new therapies outside of serotonin (such as NRIs and ketamine). However, despite the evident mode of action of these different antidepressants, there is still quite some speculation that these agents target serotonin.^{6–9} Thus, we sought to assess the effects of SSRIs, an NRI, and ketamine on brain serotonin with ultra-sensitive, niche voltammetric tools.

We chose the SSRIs because of their popularity and known target (serotonin). Mechanistically, SSRIs block serotonin transporters orthosterically (escitalopram and fluoxetine) and allosterically (escitalopram).^{37,38} We chose the NRI and ketamine because they are thought not to target serotonin. NRIs inhibit norepinephrine transporters³⁹ and ketamine is a non-competitive antagonist of NMDA receptors.⁴⁰ We administered these drugs as large, acute, therapeutically equivalent doses because this is where the most robust behavioral shifts were previously found for FST.^{41–43} We found, that despite their different modes of action, acute administration of each antidepressant caused a significant increase in basal levels of extracellular serotonin.

For SSRIs, the source of the increased serotonin levels is clear since inhibition of the serotonin transporter should allow more serotonin to accumulate in the extracellular space. Our previous work^{44–46,17} and others^{47,48} support this mechanism. For reboxetine the source is less clear since this agent targets NETs with

high affinity over the SERTs,^{49,50} and previous microdialysis studies did not find serotonin to change after this drug.⁵¹ Similarly, for ketamine a mechanism for increased serotonin is not obvious although there are reports in the literature that ketamine may increase extracellular serotonin.⁵² In the next sections, we explore in-depth our experimental findings of the mechanisms that contribute to increased serotonin for these agents.

Antidepressants that target uptake 1 and 2 increase basal serotonin

Monoamine uptake inhibition has been the frontline pharmaceutical strategy for depression. The classical view that membrane bound transporters are only responsible for clearing their name-sake substrate (i.e., SERTs for serotonin) has been significantly refined in recent years. We now know that monoamine transporters are “promiscuous” and reuptake each other’s substrates.^{53,54} Serotonin is known to be taken up via two systems: Uptake 1 and Uptake 2.⁵⁵ Briefly, as described previously, Uptake 1 is uptake via SERTs, a high-affinity, low-capacity system, whereas Uptake 2 is transport via a combination of the other monoamine transporters: DATs, NETs, OCTs, and PMATs, which is a low-affinity but high-capacity system.⁵⁶

In previous work, we discovered that ambient extracellular serotonin in the hippocampus slowly oscillates with a period of around 6–10 min, and we hypothesized that these changes may be linked to endocrine processes. We discovered that Uptake 1 or Uptake 2 inhibition differentially changed the frequency of the oscillations,⁵⁷ and thus proposed that a relationship between Uptake 1 and 2 transporters and autoreceptors controlled the frequency of the oscillations. For example, when SERTs are blocked, the high-capacity Uptake 2 system should dominate, thus the cycling speed should be faster (because of higher V_{max} taking up serotonin at a much higher rate) than in a system controlled only by SERTs (i.e., lower capacity). Conversely when NETs are blocked, the Uptake 1 system will dominate, therefore the cycling frequency should be slow compared to an Uptake 2 (high-capacity) system.

Here, we repeated the oscillation analysis for escitalopram and the other 3 agents. We found, in accord with our reasoning mentioned previously, that escitalopram and fluoxetine both increased the frequency of basal oscillations, pointing to Uptake 1 inhibition, reboxetine decreased these oscillations and ketamine had no effect. We believe that this is strong evidence showing that reboxetine plays a significant role in inhibiting serotonin reuptake via Uptake 2 inhibition. A previous microdialysis study did not find serotonin to change after reboxetine⁵¹; our method is on a fundamentally different spatial scale (the CFM is around 5 μm in diameter whereas the microdialysis probe is 100–200 μm in diameter), thus we may be able to decipher more nuanced changes. Another previous study reported that reboxetine increased raphe firing, providing support for our findings. To test this more formally, we performed FSCV analysis pre- and post-drug in the same mice. For FSCV, serotonin is electrically evoked via MFB stimulation, and we have found it can capture dynamic changes in reuptake.⁵⁸ Indeed, we found that escitalopram, fluoxetine, and reboxetine all decreased the rate of serotonin reuptake, while ketamine had no effect.

To analyze the FSCV curves, we next applied M-M analysis with a previously established model from our lab¹⁷ that incorpo-

rated both reuptake mechanisms with 2 sets of K_m and V_{max} . Using that model, we found that by only altering K_{m1} to fit the uptake curve, SERT inhibition with fluoxetine followed a classical orthosteric inhibition profile. Whereas serotonin uptake following reboxetine exhibited mainly Uptake 2 inhibition, as primarily K_{m2} was altered to fit the curve. In conjunction with the decrease in oscillatory frequency following reboxetine administration, these data clearly show that reboxetine increases basal serotonin levels via Uptake 2 inhibition.

A surprising finding of these analyses was that we could not fit the escitalopram response with the classical K_{m1} inhibition model but also had to substantially alter V_{max1} to fit the curve. Competitive uptake inhibition should not alter V_{max1} , however, escitalopram is an unusual SSRI in that it binds the SERTs both orthosterically and allosterically.⁵⁹ As it has been also postulated to be the most clinically efficacious SSRI,⁶⁰ we next focused on understanding escitalopram’s unusual reuptake kinetic profile.

Dynamic escitalopram-induced expression of serotonin transporters

From our M-M analysis of the FSCV signals, we found that we could not model the response to escitalopram with a classic orthosteric Uptake 1 inhibition and had to vary V_{max1} to fit the curve. This implies that the effects of escitalopram on SERTs transcend simple competitive uptake inhibition. This finding may be significant since there is ample evidence in the literature implying escitalopram is the most clinically efficacious antidepressant.^{60,61} Some attribute this effect to the fact that escitalopram binds the SERTs both orthosterically and allosterically.^{37,59} Thus, to further explore the effects of escitalopram on serotonin signaling, we investigated an escitalopram dose response via a set of coordinated experiments and theoretical modeling.

In separate cohorts of mice, we gave 4 different doses ($n = 4$ for each dose) of escitalopram and collected FSCV files before giving the drug, 5 min post-drug and then every 10 min post-drug for 120 min. In parallel, we investigated how the theoretical response to these doses should look under pure competitive inhibition. To this end, we created a pharmacokinetic framework model, that we coin the four-compartment model (FCM), to predict the distribution of escitalopram in the body after an *i.p.* injection. The concentration of escitalopram at a specific dose and time post-injection in the brain was used to predict the new affinity of SERTs for serotonin (apparent K_{m1} , see Materials and Methods section). The control experimental traces were modeled using our Uptake 1 and 2 reuptake M-M model. To predict changes in reuptake produced by the competitive inhibition of escitalopram, K_{m1} was replaced with the new apparent K_{m1} . Surprisingly, we found that none of the FCM responses mirrored the experimental FSCV signals and present 3 major differences given in the following text.

Evoked serotonin amplitudes were higher than those the FCM predicted

For all doses, the FCM predicted maximum amplitudes after drug to be lower than found in experiments. The experimental responses were well fit by decreasing V_{max} . A decrease in V_{max} could occur with a decreased number of transporters, which decreases the reuptake capacity.

10 minutes after each dose, reuptake rates were slower than theory predicted

10 min after each dose, all experimental reuptake rates were slower than in the predicted models. After 10 min the curves could, again, only be fit by reducing $V_{\max}$ (as mentioned previously, $V_{\max}$ can mean fewer SERTs⁶²). Rapid, SSRI-induced SERT internalization has previously been reported.⁶³ This internalization mechanism is not believed to be mediated by allosteric binding.⁵⁹ SERT trafficking to and from the membrane is regulated by kinase internal signaling pathways such as protein kinases C (PKC).⁶⁴ The mechanism of SSRI-induced SERT internalization is not yet fully defined, but the decrease in SERT surface density is analogous to PKC activation,⁶⁵ bringing forth PKC activation as a possible mechanism. SERT internalization after chronic SSRI paradigms has also been observed.⁶⁶

5 minutes after the 3 and 10 mg kg⁻¹ doses reuptake rates were faster than control

Finally, experimental reuptake rates 5 min after the 3 and 10 mg kg⁻¹ doses were faster than control, not slower, as predicted by the FCM (and general uptake inhibition theory). This phenomenon is more enigmatic than the previous two. We propose that this effect is likely compensatory (bidding to regulate increasing extracellular serotonin levels), threshold based (not present for the 1 mg kg⁻¹ dose), involves autoreceptors and runs in parallel to SERT internalization.

The clearance slopes for the 3 mg kg⁻¹ responses are not different (and sometimes faster) than the 1 mg kg⁻¹ responses. These slopes should be slower according to the FCM and general theory (i.e., more drug equals more effect). This finding implies that a compensation mechanism has been activated to counteract the increasing dose. More evidence for this comes from an FSCAV dose response for basal levels where the 3 mg kg⁻¹ response is blunted vs. the 1 mg kg⁻¹, showing compensation that is clearly overridden by 10 mg kg⁻¹.

In trying to find a mechanistic source of this compensation, 2 studies guided us. Firstly, in an elegant study, Blakely and colleagues showed a rapid and clear *increase* in serotonin reuptake activity as a result of immune system activation produced by peripheral LPS in mice.^{67,68} Secondly, we were inspired by the fact that SERTs traffic rapidly across the membrane, a phenomenon that can be experimentally modeled in murine cells.^{69,70} Therefore, we decided to study serotonin reuptake optically and with voltammetry in a cellular model of serotonergic neurons.

Knowing that escitalopram induces SERT internalization after several hours, we asked what happens after a few minutes (to mimic our dynamic *in vivo* response at 5 min). We found, in accord with the previous studies of longer time exposure (hours), that in these cells, after 5 min of escitalopram alone there were fewer SERTs on the cell surface and less ASP⁺ reuptake. However, when we stimulated the cells electrically, with KCl or serotonin, there were more serotonin transporters on the cell surface and more ASP⁺ reuptake. While the stimulations are physiologically high, the resting neurons in this model are also aphysiological in their limited ambient activity. The physiological reality *in vivo* is likely somewhere in the middle of resting and stimulated. Nonetheless, the stimulated cells mimic our *in vivo* experiment and thus are a good parallel. Additionally, in accord with our *in vivo* data, this SERT overexpression/internalization⁶³ phe-

nomenon is not induced by fluoxetine. Based on our previous work,⁵⁹ we found that citalopram and enantiomers dose-dependently induce SERT internalization and that these effects occur either in the absence or presence of a functional allosteric site. A set of voltammetric experiments in the cell model supported all these microscopic findings of dynamic escitalopram-induced increase and decreased SERT expression.

Therefore, we believe that there are parallel SERT shuttling mechanisms, one of which (overexpression) is clearly compensatory, that take effect after acute escitalopram (with the unusual property to elicit both) and that we are able to capture the first because of the rapidity of our voltammetric method. The natural question here is do these mechanisms contribute to the clinical regime where antidepressants must be taken for weeks for clinical efficacy?⁷¹ Many conjecture that SERT internalization is indeed an endpoint of antidepressant efficacy,²² we add here that perhaps the intervening weeks where patients often feel worse before they feel better may be underpinned by SERT overexpression. This should be addressed by the community in future work on this topic.

Up until now, we have proposed different mechanisms by which fluoxetine, reboxetine, and escitalopram raise serotonin extracellular levels. We next move on to investigate the processes by which ketamine has an effect on serotonin levels.

Ketamine exerts its effects on serotonin via histamine

Ketamine is a potent non-competitive NMDA receptor antagonist, conventionally used in high doses to induce anesthesia.⁴⁰ The use of acute, subanesthetic doses of ketamine to treat depressive symptoms has drastically grown in popularity for patients that are treatment-resistant.⁷² However, there are grave concerns about the long-term safety of this agent, since it is a controlled substance with well-known and potent adverse side effects.^{73,74} As the exact mechanism is unknown, several theories have been put forth on the potential antidepressant action of ketamine. Ketamine has been shown to activate the mammalian target of rapamycin (mTOR) pathway, which promotes synaptogenesis in the prefrontal cortex and hippocampus.^{75,76} This is believed to work via antagonism of NMDA receptors on GABA interneurons, which subsequently disinhibit glutamatergic neurons via AMPA receptor activation.⁷⁶ This effect has been shown to compensate for reduced neurotrophic factor expression under stress and in cases of depression.⁷⁷ This theory of synaptic plasticity and neurogenesis does not exclude the monoamine hypothesis, since SSRIs have also been shown to increase neurotrophic factor expression, which is thought to be partially induced by an increase in extracellular serotonin levels.⁷⁸ Additionally, serotonin analogs such as psychedelics have been shown to promote dendritic growth via activation of serotonin receptors.^{79,80} A parallel idea is that ketamine is an anti-inflammatory agent, as it has also been shown to attenuate pro-inflammatory cytokine levels during inflammation.⁸¹ Inflammation is almost exclusively synonymous with depression.⁸² Recently, we demonstrated *in vivo* that stress- and LPS-induced inflammation deplete extracellular serotonin levels in the brain.⁸³ Significantly, ambient serotonin levels correlated with the extent of depressive-like behavior in the mice (i.e., lower serotonin is associated with more profound depression phenotypes).⁸⁴ The mechanism for this, in part, is that inflammation-induced

histamine inhibits serotonin via inhibitory H₃ heteroreceptors on serotonin neurons.⁸⁵ We therefore decided to probe whether histaminergic modulation of serotonin is the missing link between the rise in extracellular serotonin levels after acute administration of ketamine. In the PH of mice, we saw a significant and sustained decrease in the maximum amplitude of electrically evoked histamine release 10 min after an acute injection of ketamine (20 mg kg⁻¹), and as a consequence, a disinhibition of serotonin release through H₃ receptors on serotonin terminals. It is well-known that ketamine binds to and inhibits NMDA receptors on GABA interneurons⁸⁶ (thereby disinhibiting glutamate signaling). Given that histamine neurons are also known to have NMDA receptors,⁸⁷ it is likely that ketamine inhibits histamine neurons via the NMDA receptors.

In summary, we used *in vivo* FSCV and FSCAV to measure hippocampal serotonin dynamics in mice and studied the effects of 4 different antidepressants: two SSRIs (fluoxetine and escitalopram), an NRI (reboxetine) and ketamine. We found that pseudo-equivalent doses of these drugs similarly increased ambient serotonin levels, despite their differing pharmacodynamics. Next, we took in-depth experimental and analysis approaches to understanding how these drugs modulated serotonin. Through M-M analysis, we found that changes in serotonin after SSRIs and reboxetine were due to differences in Uptake 1 and Uptake 2 mediation of serotonin reuptake and teased out critical differences between escitalopram and fluoxetine. In a cellular model of serotonergic transmission, we showed that escitalopram quickly induced SERT overexpression. Finally, we showed that ketamine modulated serotonin levels via the histamine system. Although these drugs have different pharmacodynamics, they have in common direct or indirect effects on serotonin (mechanisms illustrated in Figure S2). This finding signifies serotonin may harmonize the different theories of depression and that the community should consider how different antidepressants affect serotonin when looking at future drug design.

Limitations of the study

A limitation of this study is that the location of electrodes post-experiments could not be verified with histological analysis. This is because the carbon fiber microelectrode is so small that a damaged track cannot be visualized (with histology) in the brain area where it was placed. To mitigate this, ordinarily, we run a high voltage (13 V) through the electrode, creating a small lesion that can be visualized under an optical microscope. The nature of the current experiments (with FSCAV) is such that the electrode must be preserved at the end of the experiment to calibrate for concentration (so the lesion cannot be made).

SIGNIFICANCE

Antidepressants with different modes of action all increase extracellular serotonin via direct and indirect pathways. Unlike fluoxetine and reboxetine, escitalopram rapidly induces serotonin transporter overexpression and internalization, a unique action that is possibly a contributing factor to its supposed superior clinical efficacy. Ketamine increases serotonin levels via disinhibition of serotonin through histamine.

This work demonstrates that serotonin, when measured directly, may indicate potential antidepressant activity.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead contact
 - Materials availability
 - Data and code availability
- EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS
 - Mammalian cell culture
 - Mice
- METHOD DETAILS
 - Solutions
 - Electrode fabrication
 - Cell measurements procedures
 - Surgical procedures
 - Hardware and data collection
 - Compartmental modeling of escitalopram
- QUANTIFICATION AND STATISTICAL ANALYSIS
 - Data processing, parametric analysis and modeling of Electrochemical data
 - Statistical analysis

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.chembiol.2023.10.009>.

ACKNOWLEDGMENTS

We thank Justine Raymond for her excellent technical assistance in live cell imaging. This study was funded by the National Institutes of Health R01MH106563 (PH) and R01AG050518 (JRF), and the CAMS Lectureship Award (PH).

AUTHOR CONTRIBUTIONS

P.H.: Conceptualized, designed, and oversaw all experiments; C.E.W.: All experiments for Figures 1, 2, and 3; S.M.: All data processing and mathematical modeling; J.H. and R.S.: Live cell FSCV experiments; M.H. and A.M.B.: *in vivo* FSCV escitalopram experiments; S.N.B.: *in vivo* FSCV histamine experiments; F.H.N., M.C.R., and J.B.: Created the serotonin dual-reuptake math model; J.F.: Designed and oversaw ketamine experiments; S.L.: Live cell imaging with 1C11; P.S. and T.L.: Designed live cell imaging experiments; P.H., S.M., and B.P.: Wrote manuscript and created figures.

DECLARATION OF INTERESTS

The authors declare no competing interests.

INCLUSION AND DIVERSITY

We support inclusive, diverse, and equitable conduct of research. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper self-identifies as a member of the LGBTQIA+ community. One or more of the authors of this paper self-identifies as a gender minority in their field of research. One or more of the authors of this paper self-identifies as living with a disability.

Received: March 7, 2023
Revised: September 7, 2023
Accepted: October 12, 2023
Published: November 22, 2023

REFERENCES

- Hillhouse, T.M., and Porter, J.H. (2015). A brief history of the development of antidepressant drugs: from monoamines to glutamate. *Exp. Clin. Psychopharmacol* 23, 1–21.
- Kirsch, I. (2019). Placebo Effect in the Treatment of Depression and Anxiety. *Front. Psychiatr.* 10, 407.
- Penn, E., and Tracy, D.K. (2012). The drugs don't work? antidepressants and the current and future pharmacological management of depression. *Ther. Adv. Psychopharmacol.* 2, 179–188.
- Daws, R.E., Timmermann, C., Giribaldi, B., Sexton, J.D., Wall, M.B., Erritzoe, D., Roseman, L., Nutt, D., and Carhart-Harris, R. (2022). Increased global integration in the brain after psilocybin therapy for depression. *Nat. Med.* 28, 844–851.
- Javitt, D.C., Schoepp, D., Kalivas, P.W., Volkow, N.D., Zarate, C., Merchant, K., Bear, M.F., Umbricht, D., Hajos, M., Potter, W.Z., and Lee, C.M. (2011). Translating glutamate: from pathophysiology to treatment. *Sci. Transl. Med.* 3, 102mr2.
- Benmansour, S., Cecchi, M., Morilak, D.A., Gerhardt, G.A., Javors, M.A., Gould, G.G., and Frazer, A. (1999). Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. *J. Neurosci.* 19, 10494–10501.
- Szabo, S.T., and Blier, P. (2001). Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. *Neuropsychopharmacology* 25, 845–857.
- Gigliucci, V., O'Dowd, G., Casey, S., Egan, D., Gibney, S., and Harkin, A. (2013). Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. *Psychopharmacology (Berl)* 228, 157–166.
- López-Gil, X., Jiménez-Sánchez, L., Campa, L., Castro, E., Frago, C., and Adell, A. (2019). Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine. *ACS Chem. Neurosci.* 10, 3318–3326.
- Hersey, M., Reneaux, M., Berger, S.N., Mena, S., Buchanan, A.M., Ou, Y., Tavakoli, N., Reagan, L.P., Clopath, C., and Hashemi, P. (2022). A tale of two transmitters: serotonin and histamine as in vivo biomarkers of chronic stress in mice. *J. Neuroinflammation* 19, 167.
- MacQueen, G., and Frodl, T. (2011). The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? *Mol. Psychiatr.* 16, 252–264.
- Campbell, S., and Macqueen, G. (2004). The role of the hippocampus in the pathophysiology of major depression. *J. Psychiatry Neurosci.* 29, 417–426.
- Schmaal, L., Veltman, D.J., van Erp, T.G.M., Sämann, P.G., Frodl, T., Jahanshad, N., Loehrer, E., Tiemeier, H., Hofman, A., Niessen, W.J., et al. (2016). Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. *Mol. Psychiatr.* 21, 806–812.
- Maller, J.J., Daskalakis, Z.J., and Fitzgerald, P.B. (2007). Hippocampal volumetrics in depression: the importance of the posterior tail. *Hippocampus* 17, 1023–1027.
- MacQueen, G.M., Campbell, S., McEwen, B.S., Macdonald, K., Amano, S., Joffe, R.T., Nahmias, C., and Young, L.T. (2003). Course of illness, hippocampal function, and hippocampal volume in major depression. *Proc. Natl. Acad. Sci. USA* 100, 1387–1392.
- Malberg, J.E., and Duman, R.S. (2003). Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. *Neuropsychopharmacology* 28, 1562–1571.
- Wood, K.M., Zejda, A., Nijhout, H.F., Reed, M.C., Best, J., and Hashemi, P. (2014). Voltammetric and mathematical evidence for dual transport mediation of serotonin clearance *in vivo*. *J. Neurochem.* 130, 351–359.
- Jones, S.R., Garris, P.A., and Wightman, R.M. (1995). Different effects of cocaine and nomifensine on dopamine uptake in the caudate-putamen and nucleus accumbens. *J. Pharmacol. Exp. Therapeut.* 274, 396–403.
- Bunin, M.A., Prioleau, C., Mailman, R.B., and Wightman, R.M. (1998). Release and uptake rates of 5-hydroxytryptamine in the dorsal raphe and substantia nigra reticulata of the rat brain. *J. Neurochem.* 70, 1077–1087.
- Buc-Caron, M.H., Launay, J.M., Lamblin, D., and Kellermann, O. (1990). Serotonin uptake, storage, and synthesis in an immortalized committed cell line derived from mouse teratocarcinoma. *Proc. Natl. Acad. Sci. USA* 87, 1922–1926.
- Baudry, A., Mouillet-Richard, S., Schneider, B., Launay, J.M., and Kellermann, O. (2010). miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. *Science* 329, 1537–1541.
- Lau, T., Horschitz, S., Bartsch, D., and Schloss, P. (2009). Monitoring mouse serotonin transporter internalization in stem cell-derived serotonergic neurons by confocal laser scanning microscopy. *Neurochem. Int.* 54, 271–276.
- Samaranayake, S., Abdalla, A., Robke, R., Wood, K.M., Zejda, A., and Hashemi, P. (2015). In vivo histamine voltammetry in the mouse preammylary nucleus. *Analyst* 140, 3759–3765.
- Safer, D.J., and Zito, J.M. (2019). Short- and Long-Term Antidepressant Clinical Trials for Major Depressive Disorder in Youth: Findings and Concerns. *Front. Psychiatr.* 10, 705.
- Can, A., Dao, D.T., Arad, M., Terrillion, C.E., Piantadosi, S.C., and Gould, T.D. (2012). The mouse forced swim test. *J. Vis. Exp.* e3638.
- Yankelevitch-Yahav, R., Franko, M., Huly, A., and Doron, R. (2015). The forced swim test as a model of depressive-like behavior. *J. Vis. Exp.* 52587.
- Hendrie, C., Pickles, A., Stanford, S.C., and Robinson, E. (2013). The failure of the antidepressant drug discovery process is systemic. *J. Psychopharmacol.* 27, 407–413. discussion 413–6.
- Cryan, J.F., Markou, A., and Lucki, I. (2002). Assessing antidepressant activity in rodents: recent developments and future needs. *Trends Pharmacol. Sci.* 23, 238–245.
- Borsini, F., Podhorna, J., and Marazziti, D. (2002). Do animal models of anxiety predict anxiolytic-like effects of antidepressants? *Psychopharmacology (Berl)* 163, 121–141.
- Petit-Demouliere, B., Chenu, F., and Bourin, M. (2005). Forced swimming test in mice: a review of antidepressant activity. *Psychopharmacology (Berl)* 177, 245–255.
- Dulawa, S.C., and Hen, R. (2005). Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. *Neurosci. Biobehav. Rev.* 29, 771–783.
- Bourin, M., Fiocco, A.J., and Clenet, F. (2001). How valuable are animal models in defining antidepressant activity? *Hum. Psychopharmacol.* 16, 9–21.
- Molendijk, M.L., and de Kloet, E.R. (2015). Immobility in the forced swim test is adaptive and does not reflect depression. *Psychoneuroendocrinology* 62, 389–391.
- Sewell, F., Waterson, I., Jones, D., Tricklebank, M.D., and Ragan, I. (2021). Preclinical screening for antidepressant activity - shifting focus away from the Forced Swim Test to the use of translational biomarkers. *Regul. Toxicol. Pharmacol.* 125, 105002.
- Reardon, S. (2019). Depression researchers rethink popular mouse swim tests. *Nature* 571, 456–457.
- Detke, M.J., Johnson, J., and Lucki, I. (1997). Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. *Exp. Clin. Psychopharmacol* 5, 107–112.
- Zhong, H., Haddjeri, N., and Sánchez, C. (2012). Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action. *Psychopharmacology (Berl)* 219, 1–13.

38. Mansari, M.E., Wiborg, O., Mnie-Filali, O., Benturquia, N., Sánchez, C., and Haddjeri, N. (2007). Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. *Int. J. Neuropsychopharmacol.* **10**, 31–40.
39. Mandela, P., and Ordway, G.A. (2006). The norepinephrine transporter and its regulation. *J. Neurochem.* **97**, 310–333.
40. Zanos, P., and Gould, T.D. (2018). Mechanisms of ketamine action as an antidepressant. *Mol. Psychiatr.* **23**, 801–811.
41. Sánchez, C., and Meier, E. (1997). Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? *Psychopharmacology (Berl)* **129**, 197–205.
42. Cryan, J.F., Page, M.E., and Lucki, I. (2002). Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. *Eur. J. Pharmacol.* **436**, 197–205.
43. Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., Kavalali, E.T., and Monteggia, L.M. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. *Nature* **475**, 91–95.
44. Abdalla, A., West, A., Jin, Y., Saylor, R.A., Qiang, B., Peña, E., Linden, D.J., Nijhout, H.F., Reed, M.C., Best, J., and Hashemi, P. (2020). Fast serotonin voltammetry as a versatile tool for mapping dynamic tissue architecture: I. Responses at carbon fibers describe local tissue physiology. *J. Neurochem.* **153**, 33–50.
45. Saylor, R.A., Hersey, M., West, A., Buchanan, A.M., Berger, S.N., Nijhout, H.F., Reed, M.C., Best, J., and Hashemi, P. (2019). In vivo Hippocampal Serotonin Dynamics in Male and Female Mice: Determining Effects of Acute Escitalopram Using Fast Scan Cyclic Voltammetry. *Front. Neurosci.* **13**, 362.
46. Hersey, M., Woodruff, J.L., Maxwell, N., Sadek, A.T., Bykalo, M.K., Bain, I., Grillo, C.A., Piroli, G.G., Hashemi, P., and Reagan, L.P. (2021). High-fat diet induces neuroinflammation and reduces the serotonergic response to escitalopram in the hippocampus of obese rats. *Brain Behav. Immun.* **96**, 63–72.
47. Guiard, B.P., Mansari, M.E., Murphy, D.L., and Blier, P. (2012). Altered response to the selective serotonin reuptake inhibitor escitalopram in mice heterozygous for the serotonin transporter: an electrophysiological and neurochemical study. *Int. J. Neuropsychopharmacol.* **15**, 349–361.
48. Ceglia, I., Acconcia, S., Fracasso, C., Colovic, M., Caccia, S., and Invernizzi, R.W. (2004). Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT_{1A} receptors. *Br. J. Pharmacol.* **142**, 469–478.
49. Richelson, E., and Pfennig, M. (1984). Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. *Eur. J. Pharmacol.* **104**, 277–286.
50. Wong, E.H., Sonders, M.S., Amara, S.G., Tinholt, P.M., Piercey, M.F., Hoffmann, W.P., Hyslop, D.K., Franklin, S., Porsolt, R.D., Bonsignori, A., et al. (2000). Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. *Biol. Psychiatr.* **47**, 818–829.
51. Page, M.E., and Lucki, I. (2002). Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. *Neuropsychopharmacology* **27**, 237–247.
52. Yamamoto, S., Ohba, H., Nishiyama, S., Harada, N., Kakiuchi, T., Tsukada, H., and Domino, E.F. (2013). Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys. *Neuropsychopharmacology* **38**, 2666–2674.
53. Daws, L.C. (2009). Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. *Pharmacol. Ther.* **121**, 89–99.
54. Daws, L.C., Koek, W., and Mitchell, N.C. (2013). Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disorders. *ACS Chem. Neurosci.* **4**, 16–21.
55. Shaskan, E.G., and Snyder, S.H. (1970). Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake. *J. Pharmacol. Exp. Therapeut.* **175**, 404–418.
56. Buchanan, A.M., Parke, B., and Hashemi, P. (2021). Experimental Methods for Investigating Uptake 2 Processes In Vivo. *Handb. Exp. Pharmacol.* **266**, 101–117.
57. Witt, C.E., Mena, S., Honan, L.E., Batey, L., Salem, V., Ou, Y., and Hashemi, P. (2022). Low-Frequency Oscillations of In Vivo Ambient Extracellular Brain Serotonin. *Cells* **11**.
58. West, A., Best, J., Abdalla, A., Nijhout, H.F., Reed, M., and Hashemi, P. (2019). Voltammetric evidence for discrete serotonin circuits, linked to specific reuptake domains, in the mouse medial prefrontal cortex. *Neurochem. Int.* **123**, 50–58.
59. Matthaus, F., Haddjeri, N., Sanchez, C., Marti, Y., Bahri, S., Rovera, R., Schloss, P., and Lau, T. (2016). The allosteric citalopram binding site differentially interferes with neuronal firing rate and SERT trafficking in serotonergic neurons. *Eur. Neuropsychopharmacol.* **26**, 1806–1817.
60. Cipriani, A., Furukawa, T.A., Salanti, G., Chaimani, A., Atkinson, L.Z., Ogawa, Y., Leucht, S., Ruhe, H.G., Turner, E.H., Higgins, J.P.T., et al. (2018). Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. *Focus (Am Psychiatr Publ)* **16**, 420–429.
61. Cipriani, A., Furukawa, T.A., Salanti, G., Geddes, J.R., Higgins, J.P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I.M., McGuire, H., et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. *Lancet* **373**, 746–758.
62. Delaune, K.P., and Alsayouri, K. (2022). Physiology, Noncompetitive Inhibitor. In *StatPearls (FL: Treasure Island)*.
63. Kittler, K., Lau, T., and Schloss, P. (2010). Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. *Eur. J. Pharmacol.* **629**, 63–67.
64. Bermingham, D.P., and Blakely, R.D. (2016). Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters. *Pharmacol. Rev.* **68**, 888–953.
65. Etievant, A., Haddjeri, N., and Lau, T. (2020). Antidepressants: Molecular Aspects of SSRIs. In *Neuropsychopharmacotherapy (Springer)*, pp. 1–19.
66. Benmansour, S., Owens, W.A., Cecchi, M., Morlak, D.A., and Frazer, A. (2002). Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. *J. Neurosci.* **22**, 6766–6772.
67. Zhu, C.B., Lindler, K.M., Owens, A.W., Daws, L.C., Blakely, R.D., and Hewlett, W.A. (2010). Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. *Neuropsychopharmacology* **35**, 2510–2520.
68. Zhu, C.B., Blakely, R.D., and Hewlett, W.A. (2006). The proinflammatory cytokines interleukin-1 β and tumor necrosis factor- α activate serotonin transporters. *Neuropsychopharmacology* **31**, 2121–2131.
69. Lau, T., and Schloss, P. (2012). Differential regulation of serotonin transporter cell surface expression. *Wiley Interdisciplinary Reviews: Membrane and Transport Signaling* **1**, 259–268.
70. Lau, T., Horschitz, S., Berger, S., Bartsch, D., and Schloss, P. (2008). Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons. *FASEB J* **22**, 1702–1714.
71. Santarsieri, D., and Schwartz, T.L. (2015). Antidepressant efficacy and side-effect burden: a quick guide for clinicians. *Drugs Context* **4**, 212290.
72. Matveychuk, D., Thomas, R.K., Swainson, J., Khullar, A., MacKay, M.A., Baker, G.B., and Dursun, S.M. (2020). Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. *Ther. Adv. Psychopharmacol.* **10**, 2045125320916657.

73. Krystal, J.H., Abdallah, C.G., Sanacora, G., Charney, D.S., and Duman, R.S. (2019). Ketamine: A Paradigm Shift for Depression Research and Treatment. *Neuron* 101, 774–778.
74. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B., Jr., and Charney, D.S. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. *Arch. Gen. Psychiatry* 51, 199–214.
75. Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., Li, X.Y., Aghajanian, G., and Duman, R.S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. *Science* 329, 959–964.
76. Zunszain, P.A., Horowitz, M.A., Cattaneo, A., Lupi, M.M., and Pariante, C.M. (2013). Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. *Mol. Psychiatry* 18, 1236–1241.
77. Martinowich, K., and Lu, B. (2008). Interaction between BDNF and serotonin: role in mood disorders. *Neuropsychopharmacology* 33, 73–83.
78. Yang, T., Nie, Z., Shu, H., Kuang, Y., Chen, X., Cheng, J., Yu, S., and Liu, H. (2020). The Role of BDNF on Neural Plasticity in Depression. *Front Cell Neurosci.* 14, 82.
79. Calvin Ly, A.C.G., Cameron, Lindsay P., Wong, Jonathan M., Barragan, Eden V., Wilson, Paige C., Burbach, Kyle F., Sina Soltanzadeh, Zarandi, Alexander, Sood, Paddy, Michael R., Duim, Whitney C., Dennis, Megan Y., McAllister, A. Kimberly, Ori-McKenny, Kassandra M., Gray, John A., and Olson, David E. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. *Cell Reports* 23, 3170–3182.
80. Maxemiliano, V., Vargas, L.E.D., Chunyang Dong, Samuel J., Carter, Robert J., Tombari, Shekib A., Jami, Lindsay P., Cameron, Seona D., Patel, Joseph J., Hennessey, Hannash N., Saeger, John D., McConvy, John A., Gray, Lin Tian, and Olson, David E. (2023). Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. *Science* 379, 700–706.
81. Loix, S., De Kock, M., and Henin, P. (2011). The anti-inflammatory effects of ketamine: state of the art. *Acta. Anaesthesiol. Belg.* 62, 47–58.
82. Lee, C.H., and Giuliani, F. (2019). The Role of Inflammation in Depression and Fatigue. *Front Immunol.* 10, 1696.
83. Hersey, M., Reneaux, M., Berger, S.N., Mena, S., Buchanan, A.M., Ou, Y., Tavakoli, N., Reagan, L.P., Clopath, C., and Hashemi, P. (2022). A tale of two transmitters: serotonin and histamine as in vivo biomarkers of chronic stress in mice. *J. Neuroinflammation* 19, 167.
84. Hersey, M., Samaranayake, S., Berger, S.N., Tavakoli, N., Mena, S., Nijhout, H.F., Reed, M.C., Best, J., Blakely, R.D., Reagan, L.P., et al. (2021). Inflammation-Induced Histamine Impairs the Capacity of Escitalopram to Increase Hippocampal Extracellular Serotonin. *J. Neurosci* 41, 6564–6577.
85. Samaranayake, S., Abdalla, A., Robke, R., Nijhout, H.F., Reed, M.C., Best, J., and Hashemi, P. (2016). A voltammetric and mathematical analysis of histaminergic modulation of serotonin in the mouse hypothalamus. *J. Neurochem.* 138, 374–383.
86. Pham, T.H., and Gardier, A.M. (2019). Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. *Pharmacol. Ther.* 199, 58–90.
87. Brown, R.E., Stevens, D.R., and Haas, H.L. (2001). The physiology of brain histamine. *Prog. Neurobiol.* 63, 637–672.
88. Mouillet-Richard, S., Mutel, V., Loric, S., Tournais, C., Launay, J.M., and Kellermann, O. (2000). Regulation by neurotransmitter receptors of serotonergic or catecholaminergic neuronal cell differentiation. *J. Biol. Chem.* 275, 9186–9192.
89. Holmes, J., Lau, T., Saylor, R., Fernandez-Novell, N., Hersey, M., Keen, D., Hampel, L., Horschitz, S., Ladewig, J., Parke, B., et al. (2022). Voltammetric Approach for Characterizing the Biophysical and Chemical Functionality of Human Induced Pluripotent Stem Cell-Derived Serotonin Neurons. *Anal. Chem.* 94, 8847–8856.
90. Lau, T., Heimann, F., Bartsch, D., Schloss, P., and Weber, T. (2013). Nongenomic, glucocorticoid receptor-mediated regulation of serotonin transporter cell surface expression in embryonic stem cell derived serotonergic neurons. *Neurosci. Lett.* 554, 115–120.
91. Lau, T., Proissl, V., Ziegler, J., and Schloss, P. (2015). Visualization of neurotransmitter uptake and release in serotonergic neurons. *J. Neurosci. Methods* 241, 10–17.
92. Paxinos, G.A.F. (2007). The mouse brain atlas in stereotaxic coordinates (Elsevier).
93. Jackson, B.P., Dietz, S.M., and Wightman, R.M. (1995). Fast-scan cyclic voltammetry of 5-hydroxytryptamine. *Anal. Chem.* 67, 1115–1120.
94. Rao, N. (2007). The clinical pharmacokinetics of escitalopram. *Clin. Pharmacokinet* 46, 281–290.
95. Sogaard, B., Mengel, H., Rao, N., and Larsen, F. (2005). The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. *J. Clin. Pharmacol.* 45, 1400–1406.
96. Badea, A., Ali-Sharief, A.A., and Johnson, G.A. (2007). Morphometric analysis of the C57BL/6J mouse brain. *Neuroimage* 37, 683–693.
97. Bundgaard, C., Jorgensen, M., and Larsen, F. (2007). Pharmacokinetic modelling of blood-brain barrier transport of escitalopram in rats. *Biopharm. Drug Dispos.* 28, 349–360.
98. Kreilgaard, M., Smith, D.G., Brennum, L.T., and Sanchez, C. (2008). Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice. *Br. J. Pharmacol.* 155, 276–284.
99. Mena, S., Visentin, M., Witt, C.E., Honan, L.E., Robins, N., and Hashemi, P. (2022). Novel, User-Friendly Experimental and Analysis Strategies for Fast Voltammetry: Next Generation FSCAV with Artificial Neural Networks. *ACS Meas. Sci. Au.* 2, 241–250.
100. Hashemi, P., Dankoski, E.C., Petrovic, J., Keithley, R.B., and Wightman, R.M. (2009). Voltammetric detection of 5-hydroxytryptamine release in the rat brain. *Anal. Chem.* 81, 9462–9471.
101. Abdalla, A., Atcherley, C.W., Pathirathna, P., Samaranayake, S., Qiang, B., Pena, E., Morgan, S.L., Heien, M.L., and Hashemi, P. (2017). In Vivo Ambient Serotonin Measurements at Carbon-Fiber Microelectrodes. *Anal. Chem.* 89, 9703–9711.
102. Welch, P. (1967). The use of fast Fourier transform for the estimation of power spectra: A method based on time averaging over short, modified periodograms. *IEEE Trans. Audio. Electroacoust.* 15, 70–73.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
SERT antibodies	Advanced Targeting Systems	Product#: AB-N40
Alexa Fluor488-conjugated secondary antibodies (Donkey anti-rabbit)	Thermo Fisher Scientific	Product#: A-21026
Beta III tubulin	Abcam	Product#: ab52623
Chemicals, peptides, and recombinant proteins		
DMEM glutamax	Life Technologies	Product#: 10566016
Fetal Bovine Serum	Life Technologies	Product#: A4766801
L-glutamine	Life Technologies	Product#: 25030149
non-essential amino acids	Life Technologies	Product#: 11140050
penicillin/streptomycin	Life Technologies	Product#: 15140148
dibutyl cAMP	Sigma Aldrich	Product#: 28745
cyclohexanecarboxylic acid	Sigma Aldrich	Product#: 101834
potassium chloride	Sigma Aldrich	Product#: P3911
ASP+ (4-[4-(dimethylamino)styryl]-1-methylpyridinium iodide)	Sigma Aldrich	Product#: 336408
sterile saline (0.9% NaCl)	Hospira Mountainside Medical Equipment	Product#: 04888-10
escitalopram oxalate	Sigma Aldrich	Product#: PHR1733
urethane	Sigma Aldrich	Product#: U2500
serotonin hydrochloride	Sigma Aldrich	Product#: H9523
trizma HCl ($\text{H}_2\text{NC}(\text{CH}_2\text{OH})_2\cdot\text{HCl}$)	Sigma Aldrich	Product#: T3253
sodium chloride	Sigma Aldrich	Product#: S9625
calcium chloride	Sigma Aldrich	Product#: C5670
$\text{NaH}_2\text{PO}_4\cdot\text{H}_2\text{O}$ (sodium phosphate monobasic)	Sigma Aldrich	Product#: S0751
magnesium chloride	Sigma Aldrich	Product#: M8266
sodium sulphate	Sigma Aldrich	Product#: 239313
Nafion™ (LIQUIon, 5% w/w Nafion)	Ion Power	LQ-1105-110 EW at 5% weight
hydrochloric acid	Sigma Aldrich	Product#: 258148
paraformaldehyde	Sigma Aldrich	Product#: 158127
10X phosphate buffered saline	Sigma Aldrich	Product#: 11666789001
Dako Fluorescence Mounting Medium	Agilent (Dako Cytomation)	Product#: GM30411-2
Cellmask Deep Red Plasma Membrane stain	Thermo Fisher Scientific	Product#: C10046
(D)-+-glucose	Sigma Aldrich	Product#: G8270
HEPES	Sigma Aldrich	Product#: H4034
ketamine hydrochloride	Sigma Aldrich	Product#: 1356009
reboxetine mesylate hydrate	Sigma Aldrich	Product#: R6527
fluoxetine hydrochloride	Sigma Aldrich	Product#: 1279804
Experimental models: Cell lines		
1C11 ^{5-HT}	Brown et al. ⁸⁹	N/A
Experimental models: Organisms/strains		
Mice	Jackson Laboratory	strain: C57BL/6J
Software and algorithms		
GraphPad Prism	GraphPad Software Inc.	https://www.graphpad.com/scientific-software/prism/
WCCV 4.0	Knowmad Technologies LLC	https://techlaunch.arizona.edu/knowmad-technologies-llc

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
The Analysis Kid	Mena et al. ⁹⁷	https://analysis-kid.hashemilab.com/
Python (SciPy and Pingouin libraries)	Python	https://www.python.org/
Other		
Headstage	Pine Research Instrumentation	Product#: [NEC-HS2]
CHEM-CLAMP (potentiostat)	Dagan Corporation	Product: CHEM-CLAMP
PCIe-6341 Multifunction (I/O) DAQ	National Instruments	Product#: 781046-01
PCI-6221 Multifunction (I/O) DAQ	National Instruments	Product#: 779418-01
T-650 carbon fiber (diameter: 5–7 μm)	Goodfellow Corporation	Product#: C 005722
0.6 mm x 0.4 mm x 100 mm glass capillaries	A-M Systems, Inc.	Product#: 624500
vertical pipette puller	Narishige	Product#: P-22
silver wire (0.01 in.)	A-M Systems, Inc.	Product#: 787000
stimulating electrodes (stainless-steel 0.2 mm diameter, untwisted)	P1 Technologies	Product#: MS303/2

RESOURCE AVAILABILITY**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr. Parastoo Hashemi (phashemi@imperial.ac.uk)

Materials availability

This study did not generate new unique reagents or materials. All chemicals, antibodies, cell lines and animals used for biological studies were obtained from commercial or internal sources as described by the [key resources table](#).

Data and code availability

- All data reported in this paper will be shared by the [lead contact](#) upon request.
- The original codes used for FSCV and FSCAV analysis, including filtering, calibration, parametric analysis (Amp_{max} and $t_{1/2}$ estimations) and Michaelis-Menten fitting algorithms are implemented in a custom-designed open-source web application, ("The Analysis Kid"). This web application is publicly available at <https://github.com/sermeor/The-Analysis-Kid> as of the date of publication.
- Any additional information required to reanalyze the data reported in this paper is available from the [lead contact](#) upon request.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS**Mammalian cell culture**

1C11^{5-HT} cell culture was performed as described previously⁸⁸. Briefly, undifferentiated 1C11 cells were kept on 100 mm plates (Sarstedt) in DMEM Glutamax with 10% fetal bovine serum, 1% non-essential amino acids, 1% penicillin/streptomycin, and 1% L-glutamine (all media components by Life Technologies) at 37°C and 5% CO₂. For differentiation to serotonin neuron-like cells (1C11^{5-HT}) 10,000 cells were transferred to 8-well imaging slides (Ibidi). Then, culture medium was supplemented with 1 mM dibutyryl cAMP and 0.05% cyclohexanecarboxylic acid for 4 days (media supplements by Sigma Aldrich). Treatment conditions: For determination of SERT cell surface density, medium was supplemented with 15 mM KCl and/or 1 μM escitalopram. For ASP⁺ live cell imaging, cells were transferred to FSCV buffer (20 mM HEPES, 130 mM NaCl, 5 mM CaCl₂ and 2.5 mM glucose, optimized by Holmes et al.⁸⁹) containing 50 μM ASP⁺ and/or 1 μM escitalopram and/or serotonin (0.1 or 1 μM). Electrical stimulation was applied after perfusing the imaging slides with ASP⁺-containing FSCV buffer. Dye-free buffer was applied 1 min after electrical stimulation before image acquisition.

The cellular model used is of mouse origin, therefore no sex determination was performed. We employed the murine cell line 1C11, derived from mouse teratocarcinoma and immortalized by expression of the simian virus 40 oncogenes^{20,100}. 1C11 cells are cultures in an immature epithelial-like state and can be induced to differentiate into serotonin-neuron like cells. Serotonin neuron-like 1C11 cells were shown to display neurochemical features of adult serotonin neurons found in the raphe nuclei of mouse brain.²¹

Mice

C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME, USA) were group housed (5 males or females per cage, age: 6–12 weeks, weight: 18–30 g), with *ad libitum* access to pellet food and water, and kept on a 12 h light/dark cycle (lights on at 7:00 AM, lights off at 7:00 PM). A mixed cohort of healthy male and female mice having no previous procedures performed were used to study

the effects of different antidepressants. For the escitalopram dose-response study, male and female mice responses were segregated (Figure 2 shows female responses and male responses are in the supplemental information). All other studies in this paper show mixed sex data, as the analysis did not show significant differences between sexes. No specific randomization paradigm was implemented, but animals were chosen at random from their cages and the type of drug administered was chosen on the surgery day until the study was complete. All mouse experiments presented in this work were performed according to National Institutes of Health (NIH) guidelines and the University of South Carolina Institutional Animal Care and Use Committee (accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International) under an approved protocol.

METHOD DETAILS

Solutions

Ketamine hydrochloride (Vet One, MWI Animal Health, Boise, ID, USA), fluoxetine hydrochloride (Sigma Aldrich, St. Louis, MO, USA) and reboxetine mesylate hydrate (Sigma Aldrich, St. Louis, MO, USA), were individually dissolved in sterile saline (0.9% NaCl solution, Hospira, Mountainside Medical Equipment, Marcy, NY, USA) and administered *via* intraperitoneal injection (i.p.) at 10 mg kg⁻¹ and a volume of 5 mL kg⁻¹ body weight. Escitalopram oxalate (Sigma Aldrich, St. Louis, MO, USA) was prepared and administered following the same method at the following doses: 1 mg kg⁻¹, 3 mg kg⁻¹, 10 mg kg⁻¹ and 30 mg kg⁻¹. Urethane (Sigma Aldrich, St. Louis, MO, USA) was dissolved in sterile saline at 25% w/v and administered at 7 μ Lg⁻¹ mouse body weight for surgical anesthesia. Post-calibration solutions for FSCAV were prepared by dissolving serotonin hydrochloride (Sigma Aldrich, St. Louis, MO, USA) in Tris buffer to make solution concentrations of 10, 25, 50, and 100 nM. Tris buffer consisted of: 15 mM H₂NC(CH₂OH)₂·HCl, 140 mM NaCl, 3.25 mM KCl, 1.2 mM CaCl₂, 1.25 mM NaH₂PO₄·H₂O, 1.2 mM MgCl₂, and 2.0 mM Na₂SO₄ (Sigma Aldrich, St. Louis, MO, USA) in deionized water; the pH adjusted to 7.4 ($\pm$ 0.03).

Electrode fabrication

Carbon Fiber Microelectrodes (CFMs) were made individually by aspirating a single carbon fiber (Goodfellow Corporation, PA, USA) into a 0.6 mm x 0.4 mm glass capillary (A-M Systems Inc., Sequim, WA, USA). The capillary was then pulled in a vertical puller (Narishige, Tokyo, Japan) to create a carbon-glass seal. The exposed carbon fiber was then trimmed to 150 $\pm$ 5 μ m. Liquion (LQ-1105, 5% by weight NafionTM Ion Power, New Castle, DE, USA) was electrodeposited onto the surface of the carbon fiber by submerging the fiber in NafionTM and applying a constant potential of + 1.0 V for 30 s. The electrode was then dried at 70°C for 10 minutes and used after 24 hours.

Cell measurements procedures

SERT cell surface density was determined as described previously⁹⁰: cells were fixed in 1% paraformaldehyde/1x PBS and subsequently incubated in non-permeabilizing blocking solution (BS, 10% horse serum; 0.2% gelatin in 1x PBS; all from Sigma Aldrich, St. Louis, MO, USA). Then, SERT antibodies (Advanced Targeting Systems), diluted 1:250, were applied in BS for 60 min at room temperature. After primary antibody incubation, cells were washed three times in BS, then secondary Alexa Fluor488-conjugated antibodies (Thermo Fisher Scientific), diluted 1:1000, were incubated for 45 min at room temperature. Subsequently, cells were washed three times in 1x PBS and mounted in Dako Fluorescence Mounting Medium (Dako Cytomation). To determine ROIs for image analysis, either Cellmask Deep Red plasma membrane stain (Thermo Fisher Scientific, diluted 1:1000) was applied before fixation or tubulin immunostaining (Abcam, diluted 1:250) was employed after SERT antibody staining. For ASP+ live cell image⁹¹, cells were loaded with 50 μ M ASP+ in FSCV buffer for 1 min under the treatment conditions mentioned above. Before image acquisition, cells were transferred to ASP+ free containing buffer. To determine ROIs, a 1x working solution of Cellmask Deep Red plasma membrane stain was employed (Thermo Fisher Scientific).

Confocal image stacks were acquired using a Leica TCS SP5 Confocal imaging system mounted on a DM IRE2 microscope, equipped with an acusto-optical beam splitter, an argon ion laser (458 nm – 514 nm), a diode-pumped solid-state laser (561 nm), and a helium neon laser (633 nm). Laser lines were used as recommended for the applied dyes. Single sections of a confocal stack were acquired at 0.5 μ m steps. Confocal stacks were imported into NIH ImageJ to generate z-projections and quantify the effect of treatment conditions on fluorescence intensities. Using the channels for determination of cell boundaries ROIs were defined using the Multi Measure plugin. ROIs were then imported for quantifications into the fluorescence channels used to acquire SERT or ASP+ fluorescence signals. Fluorescence intensities measured using ImageJ were imported into GraphPadPrism software (GraphPad Software Inc., USA) to generate graphs and perform statistical analysis (variance analysis and post hoc-comparison or Student's t-test).

For FSCV measurements, cover slips with neuronal cell clusters were placed into a 35 mm low wall imaging dish (Ibidi GmbH, Martinsried, Germany) and were covered with a 2.5 mM glucose solution in HEPES buffer. The dish was then placed into a plastic holder covered with aluminum foil connected to the ground acting as a Faraday cage. Carbon fiber microelectrodes and stimulation electrodes were positioned into the cell dish, and a reference Ag/AgCl electrode (A-M Systems, Sequim, WA) was also placed in the dish under an inverted microscope (Leica DM IL LED, Wetzlar, Germany).

Surgical procedures

Mice were injected with a 25% urethane solution based on a calculation that is dependent on their weight (7 μ L g⁻¹). Following anesthetic administration, the mouse was placed into a stereotaxic system (David Kopf Instruments, Tujunga, CA, USA) where body

temperature was maintained *via* heating pad (Braintree Scientific, Braintree, MA, USA). Three holes were drilled into the skull of the mouse based on coordinates from the mouse brain atlas⁹². For serotonin measurements, the working electrode was placed in the CA2 region of the hippocampus (AP: - 2.91, ML: + 3.35, DV: - 2.50), the stimulating electrode (insulated stainless-steel, diameter 0.2 mm, untwisted, Plastics One, Roanoke, VA, USA) was placed in the MFB (AP: - 1.58, ML: + 1.00, DV: - 4.80) and the pseudo-Ag/AgCl reference electrode (made by chloritizing a silver wire in a solution of 1 M HCl for 30 s at 5 V) was placed in the opposite hemisphere of the brain as the working and stimulating electrodes. For histamine and serotonin co-measurements, the working electrode was placed in the PH (AP: -2.45, ML: + 0.50, DV: -5.45 to -5.55). Stimulation was accomplished *via* linear constant current stimulus isolator (NL800A Neurolog, Medical Systems Corp, Great Neck, NY, USA) with the following parameters: 60 Hz, 360 μ A each, 2 ms in width and 2 s in length.

Hardware and data collection

FSCV and FSCAV were performed using a Dagan Potentiostat, (Dagan Corporation, Minneapolis, MN, USA), National Instruments multifunction device USB-6341 (National Instruments, Austin, TX, USA), WCCV 4.0 software (Knowmad Technologies LLC, Tucson, AZ, USA) and a Pine Research headstage (Pine Research Instrumentation, Durham, NC, USA). The “Jackson” waveform was applied to elicit the redox properties of serotonin (0.2 V to 1.0 V to - 0.1 V to 0.2 V, 1000 V s⁻¹)⁹³. For histamine and serotonin co-measurement, the histamine waveform was applied (-0.5 V to -0.7 V to 1.1 V to -0.5 V at 600 V s⁻¹)²³. For FSCV data collection, these waveforms were applied at 10 Hz. The MFB was stimulated *in vivo* for FSCV experiments with biphasic pulses applied using a linear constant current stimulus isolator (NL800A Neurolog, Medical Systems Corp, Great Neck, NY, USA) with parameters: frequency of 60 Hz, amplitude of 360 μ A each, 2 ms in width, and 2 s of total duration (120 pulses). For cell culture experiments, the electrical stimulation consisted of biphasic pulses with the following parameters: frequency of 60 Hz, amplitude of 250 μ A each, 4 ms in width, and 1 s of total duration (60 pulses).

FSCAV consisted of 4 steps. First, the waveform was applied at 100 Hz for 2 seconds to minimize adsorption into the carbon fiber. Second, a constant potential (0.2 V) was applied for 10 seconds to allow serotonin to preconcentrate on the fiber surface. Third, the waveform was reapplied for 18 seconds to acquire the information-rich voltammograms. Finally, a waiting time of 30 seconds was given until the next file was acquired. Both for FSCV and FSCAV, the initial 10 cyclic voltammograms were averaged and subtracted from the rest of the cycling voltammograms in the color plot.

Compartmental modeling of escitalopram

The pharmacokinetic model was coded using Python generic code and solved using the SciPy library. A four compartmental model (compartments: peritoneum, plasma, periphery and brain) of the pharmacokinetics of escitalopram after intraperitoneal injection was built based on prior experiments with mice and rats. A schematic of the model is represented in Figure 3. Equations 2, 3, 4, and 5 shows the system of equations of the compartmental model.

$$\frac{dC_0}{dt} = -k_{01}C_0(t) \quad (\text{Equation 2})$$

$$\frac{dC_1}{dt} = k_{01}C_0(t) - (k_{10} + k_{12} + k_{13})(C_1(t)(1 - P_B)) + k_{21}(C_2(t)(1 - SERT_B)) + k_{31}C_3(t) \quad (\text{Equation 3})$$

$$\frac{dC_2}{dt} = k_{12}(C_1(t)(1 - P_B)) - k_{21}(C_2(t)(1 - SERT_B)) \quad (\text{Equation 4})$$

$$\frac{dC_3}{dt} = k_{13}(C_1(t)(1 - P_B)) - k_{31}C_3(t) \quad (\text{Equation 5})$$

$C_0(t)$, $C_1(t)$, $C_2(t)$ and $C_3(t)$ represent the concentration of escitalopram over time in the peritoneum, plasma, brain and periphery of the mouse body, k_{01} and k_{10} are the rate constants of diffusion from the peritoneum to plasma and secretion from plasma, k_{12} and k_{21} are the rate constants between plasma and the brain and k_{13} and k_{31} are the rate constants between plasma and the periphery, P_B represent the ratio of escitalopram binding to protein in plasma and $SERT_B$ represents the percentage of escitalopram binding to SERT in the brain.

Rate constants used for the simulation are described in Figure 3. P_B and $SERT_B$ are set to 0.56 and 0.15, respectively⁹⁴. Bioavailability of escitalopram was set to 0.80, a previously calculated bioavailability for oral administration⁹⁵, since bioavailability of intraperitoneal injection has not been studied, but it is reasonable to assume that would be between oral (0.80) and intravenous (1.00). Mouse weight was set to 20 g, the midpoint between the female mouse weight (~15 g) and male mouse weight (~25 g). Dose and volume of escitalopram solutions were dependent on mouse weight (doses: 1 mg kg⁻¹, 3 mg kg⁻¹, 10 mg kg⁻¹ and 30 mg kg⁻¹; volume: 5 mL kg⁻¹). Based on previous reports on C57BL/6J mice anatomy⁹⁶, peritoneum, plasma, brain and periphery volume were set to 2 mL, 2 mL, 0.41 mL and 15 mL, respectively. Rate constants, when available, were obtained from previous pharmacokinetic studies of escitalopram^{97,98}.

Simulated brain escitalopram concentration was used to generate synthetic FSCV signals of serotonin release and reuptake assuming escitalopram only affects serotonin reuptake *via* pure competitive inhibition of SERTs. First, Equation 1 was fitted to the

control signals. The concentration of escitalopram ([Escit.]) was then simulated at specific time points, and an apparent K_m (K_m^{app}) is calculated based on Equation 6 and assuming an inhibition constant of $K_i = 1.1$ nM for escitalopram.

$$K_m^{app} = K_m \left(1 + \frac{[Escit.]}{K_i} \right) \quad (\text{Equation 6})$$

QUANTIFICATION AND STATISTICAL ANALYSIS

Data processing, parametric analysis and modeling of Electrochemical data

FSCV files were exported from WCCV software and filtered, calibrated and analyzed using The Analysis Kid.⁹⁹ Low pass filtering of color plots was performed using a 3rd order 2D Butterworth filter with a cutoff frequency of 37.5 kHz on the x axis and 2.5 Hz on the y axis.

Serotonin and histamine were converted to concentration using calibration factors from previous *in vitro* flow injection analysis using the Jackson waveform (49.5 $\mu\text{M nA}^{-1}$ for serotonin)¹⁰⁰ and histamine waveform (11 nM nA^{-1} for serotonin and 2.825 $\mu\text{M nA}^{-1}$ for serotonin)⁸⁵. The maximum amplitude of release, Amp_{max} , was automatically detected using local maxima algorithms. The half-life of the neurotransmitter, $t_{1/2}$, was calculated by fitting an exponential curve, shown in Equation 7, from the maximum amplitude of the release and calculating the time it takes to reach 50% of the maximum concentration of the trace.

$$C(t) = C_0 \cdot e^{-kt}, t_{1/2} = \frac{\ln(2)}{k} \quad (\text{Equation 7})$$

FSCV traces were also fitted using a two-reuptake M-M model of the release and reuptake of serotonin, shown in Equation 8.

$$\frac{dC(t)}{dt} = R(t)(1 - A(t)) - \alpha \frac{V_{\text{max}1} \cdot C(t)}{K_{m1} + C(t)} - \beta \frac{V_{\text{max}2} \cdot C(t)}{K_{m2} + C(t)} \quad (\text{Equation 8})$$

Here, $R(t)$ and $A(t)$ are the release rate and autoreceptor occupancy (modulating the release term), $C(t)$ is the FSCV concentration time series, α and β are the coefficients of the two reuptake mechanisms, $V_{\text{max}1}$ and K_{m1} are the M-M parameters of the Uptake 1 mechanism (SERTs), $V_{\text{max}2}$ and K_{m2} are the M-M parameters of the Uptake 2 mechanism (OCTs, DATs and NETs). The model is semi-automatically fitted to the experimental data using a custom-designed gradient descent algorithm implemented in The Analysis Kid,⁹⁹ that uses the RMSE as cost function. The differential equation is solved using the Euler method.

FSCAV files were exported from the WCCV software and calibrated in The Analysis Kid. The third CV after the adsorption period was selected to estimate the concentration of serotonin. Charge under the serotonin Faradaic peak (numerical integral) of the selected CV was calculated using the Simpson's rule and used to predict serotonin concentration. Integration start and end points are automatically detected using local minima algorithms. To minimize the capacitive charge interference, a baseline area (charge below a line between the first and last integration points) is subtracted from the total charge. Calibration was performed using coefficients from electrode-specific linear regressions obtained from *in vitro* recordings, or a standardized neural network trained with a large *in vitro* dataset from 140 electrodes. More information on the processing methods are extensively explained elsewhere.^{99,101}

FSCAV time traces were filtered using a 3rd order bandpass Butterworth filter with cutoff frequencies of 0.0008 Hz and 0.005 Hz to study the fluctuations of serotonin. The low cutoff frequency was chosen to remove from consideration the low frequency drug effects on serotonin basal concentration. The high cutoff frequency removes the noise component of the signal.

Autocorrelation and sliding window correlation (SWC) using Pearson's correlation were used to confirm the presence of fluctuation patterns in the signals. The autocorrelation function, expressed in Equation 9, was used to calculate the correlation between pairs of samples distanced by a lag (p), where X denotes the mean value across the time series of length N .

$$r_p = \frac{\sum_{i=1}^{N-p} (X_i - \bar{X})(X_{i+p} - \bar{X})}{\sum_{i=1}^N (X_i - \bar{X})^2} \quad (\text{Equation 9})$$

SWC was used to study the correlation of fixed-length windows. Equation 10 shows the general formulation of the correlation function between a window of length l starting at time t and another window of the same length distanced by a lag p .⁵⁷

$$r_{t,p} = \frac{\sum_{s=t}^{t+l-1} (X_s - \bar{X}_s)(X_{s+p} - \bar{X}_{s+p})}{\sqrt{\left(\sum_{s=t}^{t+l-1} (X_s - \bar{X}_s)^2 \right) \left(\sum_{s=t}^{t+l-1} (X_{s+p} - \bar{X}_{s+p})^2 \right)}} \quad (\text{Equation 10})$$

Autocorrelation and SWC were calculated for all delays to study the presence of oscillatory patterns in the time series. A window length of 25 minutes was used for SWC. The power spectral density (PSD) of time series was calculated from the fast Fourier transform spectrum using the Welch method.¹⁰² Analysis of fluctuation patterns pre- and post-drug administration were performed by

comparison of the PSD peak that corresponds to the largest frequency pattern established with the correlation measurements and the spectrum density.

Statistical analysis

All statistical tests were performed using Python's SciPy and Pingouin libraries. Descriptive statistics are shown in figure legends and results as average $\pm$ SEM, and inferential significance is accepted when $p < 0.050$. Animals were excluded from the study if they passed away before the end of the experiment, or if the signal could not be obtained and/or confirmed *via* pharmacology. Sample size estimation was not performed in this study, but animal experiments of the same nature were previously performed along with a power analysis⁴⁴ which determined $n=5$ per group was enough to obtain statistical significance. This was followed in this work so as to conserve the animals utilized. FSCAV time series were statistically analyzed using analysis of covariance (ANCOVA) and Tukey-Kramer multiple comparisons between slopes. Additionally, individual time points were compared using a repeated measures analysis of variance (ANOVA) and multiple comparison paired t -tests. FSCV parameters (Amp_{max} and $t_{1/2}$) of concentration vs. time traces pre- and post-drug administration were compared using individual paired t -tests. Cell culture SERT density and ASP⁺ intensity between the different time and treatment groups were compared using Kruskal-Wallis test followed by Dunn's multiple comparisons with p -values corrected *via* Bonferroni method. Replicates (' n ') are described for each figure in the [results](#) section. All python files with statistical results are available from the [lead contact](#) upon request.